Revenue Breakdown
Composition ()
No data
Revenue Streams
Neogenomics Inc (NEO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical Services-Client direct billing, accounting for 70.4% of total sales, equivalent to $132.29M. Other significant revenue streams include Clinical Services-Commercial Insurance and Clinical Services-Medicare and Medicaid. Understanding this composition is critical for investors evaluating how NEO navigates market cycles within the Healthcare Facilities & Services industry.
Profitability & Margins
Evaluating the bottom line, Neogenomics Inc maintains a gross margin of 42.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7.55%, while the net margin is -14.45%. These profitability ratios, combined with a Return on Equity (ROE) of -12.99%, provide a clear picture of how effectively NEO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NEO competes directly with industry leaders such as ATAI and AVAH. With a market capitalization of $1.59B, it holds a significant position in the sector. When comparing efficiency, NEO's gross margin of 42.84% stands against ATAI's 100.00% and AVAH's 32.19%. Such benchmarking helps identify whether Neogenomics Inc is trading at a premium or discount relative to its financial performance.
